YOUR HEALTH. A MORE INFORMED VIEW.
Blood count, stool occult blood and a defined female tumour-marker selection for a clinician-directed assessment.
CLINICAL AUTHORDr Nirupama SabhapathySpecialist Clinical Pathology
Collected around you.THE PURPOSE BEHIND THE PANEL.
These markers are used for particular diagnostic or monitoring questions, often alongside imaging, examination or other tests. Non-cancer conditions can affect them, while some cancers do not produce a raised result. The purpose of testing should be clear before the sample is collected.
1test or panel1 included test or panel
A complete blood count describes red cells, white cells and platelets. The pattern can contribute to an assessment of anaemia, infection-related concerns or other clinical questions.
A count does not explain every abnormality. The full component list stays visible so a headline number does not hide the measurements.
1test or panel1 included test or panel
The listed stool investigation adds information that a blood sample cannot provide. Routine microscopy and occult-blood testing use different methods and answer different questions.
Neither test is a substitute for every gastrointestinal investigation. Follow the supplied collection and handling instructions.
5tests & panels5 included tests and panels
The included tumour markers may help with selected diagnostic or monitoring questions. Their usefulness depends on the reason for testing and other clinical investigations.
They are not a comprehensive cancer screen: benign conditions may raise them and some cancers do not raise them. They cannot diagnose or rule out cancer alone.
1test or panel1 included test or panel
Beta hCG is a quantitative blood measurement that can contribute to selected tumour-related investigations or monitoring. Its role depends on the clinical reason for requesting this package and the other findings.
Pregnancy and non-cancer conditions can affect interpretation. An elevated marker does not establish cancer, and a result within range does not rule it out; the clinician considers other investigations where appropriate.
KNOW EXACTLY WHAT YOU ARE CHOOSING.
The headline measurement count includes multi-component panels where present. The included test records and their published nested measurements are displayed separately so the count is transparent.
8 named tests and panels · 28 biomarkers
Reports 21 blood-cell measurements, including red cells, white cells and platelets. Explore the full component list below.
INCLUDED COMPONENTS
Looks for blood in stool that may not be visible. A positive finding does not by itself establish its cause.
Read the test guideMeasures AFP. Pregnancy, liver conditions and some tumours can affect this marker; it is not a stand-alone cancer diagnosis.
Read the test guideMeasures CA-125, a marker used in selected clinical situations, including monitoring some ovarian cancers. Benign conditions can also raise it.
Read the test guideMeasures CA 15-3, a marker sometimes used in monitoring established breast cancer. It is not a general breast cancer screening test.
Read the test guideMeasures CA 19-9, used with other investigations in selected pancreatic and biliary conditions. It cannot confirm or exclude cancer alone.
Read the test guideMeasures CEA, a marker used particularly in follow-up of some cancers. Smoking and non-cancer conditions can affect the result.
Read the test guideBeta hCG is a quantitative blood measurement that can contribute to selected tumour-related investigations or monitoring. Its role depends on the clinical reason for requesting this package and the other findings. Pregnancy and non-cancer conditions can affect interpretation. An elevated marker does not establish cancer, and a result within range does not rule it out; the clinician considers other investigations where appropriate.
Read the test guideTry a test or target name, or choose another health focus.
Checking a prescription?
Let’s make sure it matches.
THE RIGHT START DEPENDS ON YOU.
Choose the investigation around the question you want to discuss. This is not a comprehensive cancer screen, a substitute for recommended screening programmes or a way to rule out cancer.
These markers are used for particular diagnostic or monitoring questions, often alongside imaging, examination or other tests. Non-cancer conditions can affect them, while some cancers do not produce a raised result. The purpose of testing should be clear before the sample is collected.
Compare the full included list with your clinician’s request. This is not a comprehensive cancer screen, a substitute for recommended screening programmes or a way to rule out cancer.
Bring earlier results and the relevant symptom or treatment history. The clinician can decide whether this scope, a smaller test selection or a different investigation is the most useful next step.
MAKE THE SAMPLE COUNT.
Preparation follows the actual specimen and tests in Cancer Markers (Female). Confirm your personal instructions before collection.
A personal checklist. Your care team confirms the instructions.
YOUR COLLECTION. YOUR CHOICE.
Both routes lead to the same defined package. Choose the location during checkout; this package waives the collection fee for its visit.
YOUR PLACE. THE SAME LABORATORY PATHWAY.
Discuss collection at your home, hotel or workplace in Dubai. The care team confirms the appropriate specimen, preparation and collection arrangements for this package.
Across DubaiTHE LABORATORY. READY TO WELCOME YOU.
Intel Lab · Deira
101–102, Al Hawai Building, Al Rigga Road, Al Muraqqabat, Deira, Dubai
DEIRA · DUBAI101–102Al Hawai Building
Al Rigga Road
FROM BOOKING TO UNDERSTANDING.
Follow Cancer Markers (Female) from your care bag to an informed conversation.
The right package. The right person.
Add Cancer Markers (Female) to your care bag. Book for yourself or assign the package to someone else. The care team can help match the selection to a request or prescription.
Preparation follows the test.
Confirm the instructions for blood + stool and the appropriate collection arrangements. Correct identification, specimen choice and timing support a useful result.
Laboratory work, behind the finding.
Intel Lab processes the sample and checks the report. The package lists 48 hours; collection timing and any additional laboratory checks may affect release.
A finding, placed in your context.
Read the report with the reason for testing. A clinician can explain unexpected findings, relevant limitations and whether any further assessment is appropriate.
MORE THAN A LIST OF NUMBERS.
Your report brings the measurements together. Explore the findings below to see which questions make the report more meaningful.
UNDERSTANDING YOUR REPORTBlood
The result describes the sample that was tested. Preparation, timing and the measurement method help explain its context.
RESULT + CONTEXT
A complete blood count describes red cells, white cells and platelets. The pattern can contribute to an assessment of anaemia, infection-related concerns or other clinical questions. A count does not explain every abnormality. The full component list stays visible so a headline number does not hide the measurements.
UNDERSTANDING YOUR REPORTStool
The result describes the sample that was tested. Preparation, timing and the measurement method help explain its context.
RESULT + CONTEXT
The listed stool investigation adds information that a blood sample cannot provide. Routine microscopy and occult-blood testing use different methods and answer different questions. Neither test is a substitute for every gastrointestinal investigation. Follow the supplied collection and handling instructions.
UNDERSTANDING YOUR REPORTBlood
The result describes the sample that was tested. Preparation, timing and the measurement method help explain its context.
RESULT + CONTEXT
The included tumour markers may help with selected diagnostic or monitoring questions. Their usefulness depends on the reason for testing and other clinical investigations. They are not a comprehensive cancer screen: benign conditions may raise them and some cancers do not raise them. They cannot diagnose or rule out cancer alone.
UNDERSTANDING YOUR REPORTBlood
The result describes the sample that was tested. Preparation, timing and the measurement method help explain its context.
RESULT + CONTEXT
Beta hCG is a quantitative blood measurement that can contribute to selected tumour-related investigations or monitoring. Its role depends on the clinical reason for requesting this package and the other findings. Pregnancy and non-cancer conditions can affect interpretation. An elevated marker does not establish cancer, and a result within range does not rule it out; the clinician considers other investigations where appropriate.
THE NEXT STEP IS PERSONAL.
Connect the laboratory findings with the reason for this specific test. A report supports the next clinical conversation; it does not decide it for you.
Discuss each relevant marker with the clinician who requested it. A raised value needs context and a normal value does not exclude cancer; further tests depend on the specific clinical question.
Discuss this result with a clinician who knows the reason for testing. Further investigations or follow-up depend on the actual findings and your circumstances.
THE LABORATORY BEHIND YOUR RESULTS.
Intelligent Care brings the collection to you. Intel Lab brings the laboratory pathway, from sample handling to reporting.
Accurate patient details, the correct specimen and clear collection instructions are the first part of a reliable laboratory pathway. Follow the collection team’s instructions for the specimens required by this panel.
The laboratory’s analytical work and quality processes support the measurements in the report. Explore the laboratory’s published quality standards and accreditation scope for the detail behind its services.
Reporting connects the laboratory findings with their clinical use. Unexpected or significant results may need additional checks or communication with the referring clinician.
EXPERTISE WITH A NAME.
Laboratory content belongs with laboratory expertise. Explore the clinical profiles and their Dubai Health Authority directory records.
Clinical author
Laboratory Director · Intel Lab
Dr Nirupama Sabhapathy is a DHA-licensed Specialist in Clinical Pathology at Intel Lab. Her published Intel Lab profile describes more than 25 years in medicine and her role as Laboratory Director.
Clinical reviewer
Specialist Clinical Pathology · Intel Lab
Dr Joyce Jose is a DHA-licensed Specialist in Clinical Pathology at Intel Lab. Her public professional record includes pathology practice in the UAE and earlier experience as a professor at Gulf Medical University.
CHOOSE BY PURPOSE, NOT JUST COUNT.
Related packages may ask different questions. Compare their actual scope and discuss which, if any, is appropriate for you.
You are viewingA defined selection of tumour markers, with a blood count and stool occult blood, for clinician-directed assessment. These results cannot confirm or rule out cancer on their own.
Blood count, liver, kidney, cholesterol, blood sugar and urine tests: the essentials in one visit.
A broad whole-body screen covering blood, urine and stool with kidney, liver, lipid, iron, diabetes and vitamin markers.
Our most complete checkup: everything in Elite plus advanced cardiac and metabolic markers (hs-CRP, homocysteine, insulin and more).
Choosing for a particular need?
We can help you read the options.
BEFORE YOU BOOK.
Preparation, sample types, timing and what the package does—and does not—include.
Blood count, stool occult blood and a defined female tumour-marker selection for a clinician-directed assessment. The full named inventory on this page is the scope of the package.
No. Some cancers do not raise these markers. Likewise, an elevated marker does not establish cancer; the clinical context and further investigations determine its significance.
Yes. Benign conditions, inflammation and other factors may raise some tumour markers. The marker and the clinical context matter.
No. Appropriate screening may involve imaging, cervical screening, stool-based programmes or other approaches depending on age and risk.
In selected established conditions, trends may support monitoring. A one-off value and a follow-up trend answer different questions.
This package does not require fasting for this testing. Confirm whether any additional tests in your booking change that instruction; do not alter prescribed medicines without advice.
Yes. Choose home collection across Dubai or a visit to Intel Lab in Deira. Any health package waives the collection fee for its own visit; separate appointments are assessed separately.
The package price is AED 499; the listed turnaround is 48 hours. Confirm collection and processing arrangements with the team. Turnaround is not a guarantee that every result will be released at one exact time.
Review relevant findings with a qualified clinician alongside the reason for testing, symptoms, medicines and prior results. The report may lead to reassurance about the tested question, confirmation, a targeted investigation or follow-up—not an automatic treatment decision.
YOUR NEXT STEP. AROUND YOU.
Cancer Markers (Female) · 28 biomarkers · Blood + Stool